Galectin Therapeutics Inc., a clinical-stage biopharmaceutical company focused on therapies for fibrotic diseases and cancer, reported its financial results for the three and nine months ended September 30, 2024. The company experienced a net loss of $11.2 million for the third quarter, compared to a loss of $10.4 million in the same period of 2023. For the nine months ended September 30, 2024, the net loss increased to $35.1 million from $31.1 million in the prior year. Despite the increase in losses, the net loss applicable to common stockholders for the third quarter improved to $11.2 million from $14.0 million year-over-year, resulting in a net loss per share of $(0.18), down from $(0.24).

Total operating expenses for the third quarter were $9.1 million, slightly lower than the $9.2 million reported in the same quarter of 2023. However, for the nine-month period, operating expenses rose to $30.0 million from $28.5 million, primarily driven by increased clinical activities related to the NAVIGATE clinical trial.

As of September 30, 2024, Galectin Therapeutics reported cash and cash equivalents of $27.1 million, an increase from $20.4 million at the end of the third quarter in 2023. The company’s total current assets rose to $28.7 million, while total liabilities surged to $121.5 million, up from $88.4 million at the end of 2023. The increase in liabilities was attributed to a rise in current liabilities, which reached $25.3 million, compared to $15.7 million at the end of 2023.

The company has entered into a $6 million line of credit financing agreement with its chairman, Richard E. Uihlein, on November 14, 2024, to support its operations. Despite this, there remains substantial doubt about the company's ability to continue as a going concern beyond May 2025, as it relies heavily on external capital for future operations.

Galectin Therapeutics is actively conducting the NAVIGATE trial, with topline results expected in December 2024. The trial evaluates the efficacy of its lead compound, belapectin, in preventing esophageal varices in patients with metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis. The company has also been exploring belapectin's potential in cancer immunotherapy, with ongoing preclinical and clinical trials.

Overall, while the company has made strides in its clinical programs, it continues to face significant financial challenges and operational uncertainties.

About GALECTIN THERAPEUTICS INC

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.